The deadly impact of extreme drug resistance in Acinetobacter baumannii

Critical Care Medicine

Volumn 42, Issue 5, 2014, Pages 1289-1291

  Spellberg, Brad ^a,b   Bonomo, Robert A ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter baumannii; carbapenem resistance; extreme drug resistance

Indexed keywords

DOCTOR PATIENT RELATION; DYING; EDITORIAL; HEALTH CARE QUALITY; HOSPICE; HUMAN; INTENSIVE CARE UNIT; INTENSIVIST; LENGTH OF STAY; PALLIATIVE THERAPY; PATIENT TRANSPORT; PRIORITY JOURNAL; TERMINAL CARE; TERMINALLY ILL PATIENT; VENTILATED PATIENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; FEMALE; HUMANS; IMIPENEM; MALE;

EID: 84899491308     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000181     Document Type: Editorial

References (25)

1. Glew RH, Moellering RC Jr, Kunz LJ: Infections with Acinetobacter calcoaceticus (Herellea vaginicola): Clinical and laboratory studies. Medicine (Baltimore) 1977; 56:79-97
2. Seifert H, Strate A, Pulverer G: Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74:340-349
3. Tilley PA, Roberts FJ: Bacteremia with Acinetobacter species: Risk factors and prognosis in different clinical settings. Clin Infect Dis 1994; 18:896-900
4. Joly-Guillou ML: Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11:868-873
5. Melsen WG, Rovers MM, Groenwold RH, et al: Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13:665-671
6. Sorbello A, Komo S, Valappil T: Noninferiority margin for clinical trials of antibacterial drugs for nosocomial pneumonia. Drug Inform J 2010; 44:165-176
7. Spellberg B, Talbot G, for the Infectious Diseases Society of America (IDSA), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), and Society of Critical Care Medicine (SCCM): Recommended design features of future clinical trials of anti-bacterial agents for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Clin Infect Dis 2010; 51:S150-S170
8. Muscedere JG, Shorr AF, Jiang X, et al; Canadian Critical Care Trials Group: The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: An important determinant of outcome. J Crit Care 2012; 27:322.e7-322.e14
9. Shlaes DM, Sahm D, Opiela C, et al: The FDA reboot of antibiotic development. Antimicrob Agents Chemother 2013; 57:4605-4607
10. Dizbay M, Tunccan OG, Sezer BE, et al: Nosocomial imipenem-resistant Acinetobacter baumannii infections: Epidemiology and risk factors. Scand J Infect Dis 2010; 42:741-746
11. Park YK, Peck KR, Cheong HS, et al: Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009; 15:1325-1327
12. Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329
13. Munoz-Price LS, Zembower T, Penugonda S, et al: Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: Study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 2010; 31:1057-1062
14. Chung DR, Song JH, Kim SH, et al; Asian Network for Surveillance of Resistant Pathogens Study Group: High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184:1409-1417
15. Erbay A, Idil A, Gözel MG, et al: Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009; 34:575-579
16. Song JY, Cheong HJ, Choi WS, et al: Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol 2011; 60:605-611
17. Lee H-Y, Chen C-L, Wu S-R, et al: Risk Factors and Outcome Analysis of Acinetobacter baumannii Complex Bacteremia in Critical Patients. Crit Care Med 2014; 42:1081-1088
18. Gundi VA, Dijkshoorn L, Burignat S, et al: Validation of partial rpoB gene sequence analysis for the identification of clinically important and emerging Acinetobacter species. Microbiology 2009; 155:2333-2341
19. Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-582
20. Kwon KT, Oh WS, Song JH, et al: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59:525-530
21. Joung MK, Kwon KT, Kang CI, et al: Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 2010; 61: 212-218
22. Esterly JS, Griffith M, Qi C, et al: Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 2011; 55:4844-4849
23. Huang ST, Chiang MC, Kuo SC, et al: Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2012; 45:356-362
24. Lemos EV, de la Hoz FP, Einarson TR, et al: Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: Systematic review and meta-analysis. Clin Microbiol Infect 2013 Aug 24. [Epub ahead of print]
25. Spellberg B, Bartlett JG, Gilbert DN: The future of antibiotics and resistance. N Engl J Med 2013; 368:299-302